Stentys (www.stentys.com) announced today that it has appointed a Scientific Advisory Board (SAB) that includes some of the most prominent names in cardiology. Stentys is the first company to develop the next-generation of dedicated drug-eluting stents for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.
